Next 10 |
Tinlarebant is Belite Bio’s orally administered tablet intended to slow disease progression in patients affected with Stargardt Disease (STGD1) and Geographic Atrophy (GA) in advanced Dry Age-related Macular Degeneration (Dry AMD) Data from a 24-month Phase 2 trial in adolescent STGD1 ...
2024-04-26 05:02:26 ET More on Belite Bio Belite Bio, Inc (BLTE) Q4 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Belite Bio Historical earnings data for Belite Bio Financial information for Belite Bio Read the full article on...
SAN DIEGO, April 25, 2024 (GLOBE NEWSWIRE) -- Belite Bio , Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have sign...
2024-04-20 01:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-03-31 04:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Tinlarebant is Belite Bio’s orally administered tablet intended to slow disease progression in patients affected with Stargardt Disease (STGD1) and Geographic Atrophy (GA) in advanced Dry Age-related Macular Degeneration (Dry AMD) Data from a 24-month Phase 2 trial in adolescent STGD1 ...
2024-03-12 19:53:07 ET Belite Bio, Inc (BLTE) Q4 2023 Results Conference Call March 12, 2024 04:30 PM ET Company Participants Tom Lin - Chiarman and Chief Executive Officer Nathan Mata - Chief Scientific Officer Hao-Yuan Chuang - Chief Financial Officer Con...
Koninklijke KPN NV (KKPNF) is expected to report for Q4 2023 ECA Marcellus Trust I Unit (ECTM) is expected to report for Q4 2023 San Juan Basin Royalty Trust (SJT) is expected to report for Q4 2023 Avenir Wellness Solutions Inc (AVRW) is expected to report for Q4 2023 Carmell Corp...
2024-03-12 01:13:14 ET More on Belite Bio Seeking Alpha’s Quant Rating on Belite Bio Historical earnings data for Belite Bio Financial information for Belite Bio Read the full article on Seeking Alpha For further details see: Belite Bio GAA...
SAN DIEGO, March 11, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that its annual ...
News, Short Squeeze, Breakout and More Instantly...
Belite Bio Inc Company Name:
BLTE Stock Symbol:
NASDAQ Market:
Tinlarebant is Belite Bio's orally administered tablet intended to slow disease progression in patients affected with Stargardt Disease (STG...
Tinlarebant is Belite Bio’s orally administered tablet intended to slow disease progression in patients affected with Stargardt Disease (STGD1) and Geographic Atrophy (GA) in advanced Dry Age-related Macular Degeneration (Dry AMD) Data from a 24-month Phase 2 trial in adolescent STGD1 ...
SAN DIEGO, April 25, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ:BLTE) ("Belite Bio" or the "Company"), a clinical-stage biopharmaceutical ...